Published in Arch Surg on February 01, 1998
Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg (2000) 4.44
Hepatocellular carcinoma--cause, treatment and metastasis. World J Gastroenterol (2001) 3.95
Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg (2001) 3.25
Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg (1999) 3.05
Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg (2002) 2.42
The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol (2002) 2.03
A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg (2007) 1.63
Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol (2006) 1.60
Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified? Ann Surg (2002) 1.45
Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg (2003) 1.35
Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg (2003) 1.27
Current management of hepatocellular carcinoma. World J Gastroenterol (2014) 1.14
Preventive treatments for recurrence after curative resection of hepatocellular carcinoma--a literature review of randomized control trials. World J Gastroenterol (2003) 1.09
Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas. Surgery (2007) 1.06
Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J Gastroenterol (2004) 1.01
Prevention of recurrence after curative treatment for hepatocellular carcinoma. Surg Today (2012) 0.90
Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis. Oncotarget (2015) 0.90
Influence of hepatic arterial blockage on blood perfusion and VEGF, MMP-1 expression of implanted liver cancer in rats. World J Gastroenterol (2002) 0.89
Resection of hepatitis B virus-related hepatocellular carcinoma: evolving strategies and emerging therapies to improve outcome. World J Gastroenterol (2014) 0.85
Surgical strategy for liver cancers in the era of effective chemotherapy. Liver Cancer (2013) 0.84
A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma. Can J Gastroenterol (2013) 0.83
Adjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete hepatectomy: a randomized controlled trial. PLoS One (2013) 0.81
Lipiodolized transarterial chemoembolization in hepatocellular carcinoma patients after curative resection. J Cancer Res Clin Oncol (2013) 0.81
Surgical treatment of hepatocellular carcinoma: evidence-based outcomes. World J Gastroenterol (2008) 0.78
RMP predicts survival and adjuvant TACE response in hepatocellular carcinoma. Oncotarget (2015) 0.77
The prognostic factor for outcome following second resection for intrahepatic recurrence of hepatocellular carcinoma with a hepatitis B virus infection background. J Cancer Res Clin Oncol (2005) 0.77
Risk factors for residual tumor after resection of hepatocellular carcinoma. World J Gastroenterol (2011) 0.76
A novel scoring system predicts adjuvant chemolipiodolization benefit for hepatocellular carcinoma patients after hepatectomy. Oncotarget (2016) 0.75
Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma. World J Surg Oncol (2016) 0.75
Conventional oral systemic chemotherapy for postoperative hepatocellular carcinoma: A systematic review. Mol Clin Oncol (2014) 0.75
Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence. Oncol Lett (2016) 0.75
Glutamine synthetase predicts adjuvant TACE response in hepatocellular carcinoma. Int J Clin Exp Med (2015) 0.75
Successful surgical resection for peritoneal implantation of hepatocellular carcinoma at the paracardial portion. J Oncol (2009) 0.75
Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma. Cell Death Dis (2017) 0.75
A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases (2015) 0.75
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology (2010) 12.32
Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science (1999) 7.66
NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Mol Cell (1998) 7.58
Early treatment of acute biliary pancreatitis by endoscopic papillotomy. N Engl J Med (1993) 5.84
Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor. Science (2001) 5.25
Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J (2000) 5.22
Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg (1999) 4.97
A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell (1999) 4.65
Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg (2000) 4.44
Endoscopic biliary drainage for severe acute cholangitis. N Engl J Med (1992) 4.29
Identification and characterization of variable-number tandem repeats in the Yersinia pestis genome. J Clin Microbiol (2001) 4.08
Prospective randomized study of early versus delayed laparoscopic cholecystectomy for acute cholecystitis. Ann Surg (1998) 3.43
Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg (2001) 3.25
Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer (2000) 3.23
A prospective study on fish bone ingestion. Experience of 358 patients. Ann Surg (1990) 3.19
Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg (1999) 3.05
Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg (1995) 3.04
Francisella tularensis strain typing using multiple-locus, variable-number tandem repeat analysis. J Clin Microbiol (2001) 2.99
Anterior approach for difficult major right hepatectomy. World J Surg (1996) 2.94
A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. Proc Natl Acad Sci U S A (1991) 2.93
Prospective evaluation of Pringle maneuver in hepatectomy for liver tumors by a randomized study. Ann Surg (1997) 2.83
Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors. J Biol Chem (1997) 2.73
Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia. Circ Res (2001) 2.55
Compliance with postoperative instructions: a telephone survey of 750 day surgery patients. Anaesthesia (2001) 2.53
Mismatch repair co-opted by hypermutation. Science (1998) 2.49
Hepatocellular carcinoma in the elderly: results of surgical and nonsurgical management. Am J Gastroenterol (1999) 2.47
Adult-to-adult living donor liver transplantation using extended right lobe grafts. Ann Surg (1997) 2.44
Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis. Arch Surg (1995) 2.37
alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol (2000) 2.36
Preoperative endoscopic drainage for malignant obstructive jaundice. Br J Surg (1994) 2.22
A human T lymphocyte differentiation marker defined by monoclonal antibodies that block E-rosette formation. J Immunol (1981) 2.20
HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene (2007) 2.19
Effects of the intermittent Pringle manoeuvre on hepatic gene expression and ultrastructure in a randomized clinical study. Br J Surg (2003) 2.19
beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer (2001) 2.17
Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol (2001) 2.15
Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Natl Acad Sci U S A (2000) 2.13
Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg (2003) 2.10
Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg (1997) 2.09
Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. Aliment Pharmacol Ther (2014) 2.06
Familial colorectal cancer risk by subsite of primary cancer: a population-based study in Utah. Aliment Pharmacol Ther (2015) 2.03
Distribution and molecular analysis of Lyme disease spirochetes, Borrelia burgdorferi, isolated from ticks throughout California. J Clin Microbiol (1993) 2.03
The clinical significance of routine histopathologic study of the resected appendix and safety of appendiceal inversion. Surg Gynecol Obstet (1986) 2.02
Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal. Ann Surg (2000) 2.01
Cilia with defective radial spokes: a cause of human respiratory disease. N Engl J Med (1979) 2.01
A prospective study of operative risk factors in perforated duodenal ulcers. Ann Surg (1982) 2.00
Two cases of acrometastasis to the hands and review of the literature. Curr Oncol (2008) 2.00
The Shatin community mental health survey in Hong Kong. II. Major findings. Arch Gen Psychiatry (1993) 1.99
Pancreatic solid-cystic-papillary tumor: clinicopathologic features in eight patients from Hong Kong and review of the literature. World J Surg (1999) 1.98
Hepatectomy with an ultrasonic dissector for hepatocellular carcinoma. Br J Surg (1996) 1.97
Analysis of reduced death and complication rates after esophageal resection. Ann Surg (2001) 1.96
Adaptive radiation therapy. Phys Med Biol (1997) 1.94
Management of spontaneous rupture of hepatocellular carcinoma: single-center experience. J Clin Oncol (2001) 1.93
Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med (1994) 1.93
Early versus delayed laparoscopic cholecystectomy for treatment of acute cholecystitis. Ann Surg (1996) 1.92
The bacteriology and septic complication of patients with appendicitis. Ann Surg (1984) 1.89
Risk factors for perioperative morbidity and mortality after extended hepatectomy for hepatocellular carcinoma. Br J Surg (2003) 1.88